ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic...